🟢 Telix Pharmaceuticals is trading 6.5% up today after completing 350-patient Phase 3 BiPASS enrollment

Telix Pharmaceuticals is trading at $11.56, up +6.54% on September 2, 2026, after completing enrollment of 350 patients in the Phase 3 BiPASS study.

• Aligned with the FDA on a potential NDA pathway for pre-biopsy prostate-cancer imaging using Illuccix and Gozellix, potentially supporting reimbursement and broader access.
• Healthcare-sector strength provides additional support, but the company-specific catalyst is the primary driver.